Results 91 to 100 of about 53,817 (192)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

, 2012
Silke Walleser,1 Joshua Ray,2 Helge Bischoff,3 Alain Vergnenègre,4 Hubertus Rosery,5 Christos Chouaid,6 David Heigener,7 Javier de Castro Carpeño,8 Marcello Tiseo,9 Stefan Walzer21Health Economic Consultancy, Renens, Switzerland; 2F
Ray J., Rosery H., Ray J, Vergnenègre A, Chouaid C., Rosery H, Heigener D, Tiseo M, Tiseo M., Vergnenegre A., Walzer S, Bischoff H., de Castro Carpeño J, Walzer S., Bischoff H, Chouaid C, Walleser S., Walleser S, Carpeno J. C., Heigener D.   +19 more
core  

Synergistic inhibition of cell growth and EGFR/Akt signaling in erlotinib-resistant FaDu cells by miR-7 and erlotinib.

, 2012
(A) Cell titre analysis of FaDu cells that were transfected with vehicle only (LF2000), miR-7, or miR-NC for 3 d, and then treated with erlotinib (7.5 µM) or vehicle (DMSO) for a further 4 d.
Rebecca J. Webster (125658), Peter J. Leedman (125661), Patrick A. Candy (125650), Michael R. Epis (125655), Alishum Ali (125651), Clarissa Ganda (125653), Keith M. Giles (125649), Felicity C. Kalinowski (125648)   +7 more
core   +1 more source

Genotype‐directed therapy for non–small cell lung cancer diagnosed during pregnancy: A pooled analysis of seven cases from the Cancer and Pregnancy Registry with maternal and neonatal outcomes and review of the literature

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 10, Page 2089-2096, October 2026.
In this retrospective case series from a single database of pregnant women with cancer, seven were diagnosed with non‐small cell lung cancer (NSCLC). Chemotherapy and in some cases also biomarker‐directed therapy during pregnancy were associated with disease control allowing delivery closer to term and resulting in improved maternal outcomes compared ...
Reed Firestone, John Gaughan, Elyce Cardonick   +2 more
wiley   +1 more source

Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy

, 2015
Hongying Sui, Caixia Shi, Zhipeng Yan, Hucheng LiDepartment of Gynecological Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha City, People’s Republic of ...
Li H, Yan Z, Shi C, Sui H
core  

Erlotinib-Induced Rash Spares Previously Irradiated Skin

, 2011
Background: Erlotinib is an epidermal growth factor receptor inhibitor prescribed to patients with locally advanced or metastasized non-small cell lung carcinoma after failure of at least one earlier chemotherapy treatment.
Ronald H. Houwing, Vonk, E.J.A., Lips, I.M., Houwing, R.H., Koster, M.E.Y., Ernest J. A. Vonk, Mariska E. Y. Koster, Irene M. Lips   +7 more
core   +1 more source

Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment [PDF]

, 2012
9 páginas, 7 figurasInhibitors of the tyrosine kinase activity of epidermal growth factor receptor, as erlotinib, have an established role in treating several cancer types.
Sancho, M, Pérez-Payá, E, Orzáez, M., Guevara, Tatiana, Pérez-Payá, Enrique, Guevara, T, Orzáez, M, Sancho, M.   +7 more
core   +1 more source

Clinical and Imaging Features of Tepotinib‐Induced Interstitial Lung Disease in the Post‐Marketing Setting in Japan

Cancer Science, Volume 117, Issue 10, Page 2827-2837, October 2026.
This article reports on the clinical and imaging features of tepotinib‐induced interstitial lung disease (ILD), which were evaluated by an ILD adjudication committee composed of external respiratory and radiology experts, and the committee expertly identified 35 patients with tepotinib‐induced ILD from spontaneous adverse event reports accumulated in ...
Terufumi Kato, Tomohisa Baba, Masahiro Endo, Shehla Endo, Eisuke Horii, Masahiko Kusumoto   +5 more
wiley   +1 more source

Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha

, 2007
OBJECTIVE: To examine whether erlotinib gives similar results to gefitinib, a small molecule epidermal growth factor receptor (HER1/EGFR) tyrosine kinase (TK) inhibitor that inhibits the growth of human bladder cancer cell lines in vitro, and given that ...
Brenner, Phillip C., Hayes, Vanessa, Russell, Pamela, Qu, Xian-Jun, Yang, Jia-Lin, Goldstein, David, Brenner, Phillip, Russell, Pamela J., Hayes, Vanessa M.   +8 more
core   +1 more source

GRHL2-HER3 and E-cadherin mediate EGFR-bypass drug resistance in lung cancer cells

Frontiers in Cell and Developmental Biology
Epidermal growth factor receptor (EGFR) is a major oncogenic protein, and thus EGFR-targeting therapies are widely used in patients with various types of cancer, including lung cancer. However, resistance to EGFR inhibitors, such as erlotinib, presents a
Fumiya Ito, Wakiko Iwata, Yoshihiro Adachi, Hiromi Sesaki, Miho Iijima   +4 more
doaj   +1 more source

Extraordinary and prolonged Erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report

, 2017
Elisabetta Gambale,1 Consiglia Carella,1 Paolo Amerio,2 Fiamma Buttitta,3 Rosa Lucia Patea,4 Clara Natoli,1 Michele De Tursi1 1Medical Oncology Unit, Department of Medical, Oral and Biotechnological Sciences, 2Department of Dermatology and Venereology ...
Patea RL, De Tursi M, Buttitta F, Natoli C, Gambale E, Amerio P, Carella C   +6 more
core